Clinical Trials Logo

Clinical Trial Summary

Drug prescriptions are usual during pregnancy however women and their fetuses still remain an orphan population with regard to drugs efficacy and safety clinical studies. Most xenobiotics diffuse through the placenta and some of them can alter fetus development resulting in structural abnormalities, growth or functional deficiencies. The aim of the study is to study the drug transfer using human placenta after delivery.


Clinical Trial Description

For ethical reasons, pregnant woman are not included in clinical trials so that data regarding safety and efficacy of many drugs are scarce. It is known that xenobiotics across the placental barrier but studies regarding quantity and mechanisms of this transfer remain insuffisant. Among the different methodologies to evaluate drug transfer, perfusion of human cotyledon is one of the most relevant ones. The two sides of the cotyledon, fetal and maternal ones, are perfused within the hour after delivery with EARLE medium in a double closed circuit. The studied drug (it can be any drug given to pregnant mothers) and antipyrine (the control molecule) are added at the beginning of the three hours perfusion realized at 37°C, with maternal flow rate of 12ml/min and fetal one of 6ml/min. Samples are collected along the perfusion and the drugs dosage will be done in the pharmacology department of Cochin Hospital. Tissues of the cotyledon will be also collected to study the proteins, and ARNs expressed. The drug concentrations will be analyzed by calculating fetal to maternal concentrations ratios and a fetal transfer rate (fetal drug quantity on total drug quantity at the end of the perfusion). Then modelling on Monolix software will be done to estimate the transfer constants across the two compartments. Modelling will allow to estimate the interindividual variability and to test covariables like sex, gestation duration, genetics, or protein expression. Proteins will be studied by an appropriated method (western blot, or proteomic analysis). The genetics study will consist in candidate gene approach. Polymorphisms will be chosen in genes coding for transporters or enzymes or their regulators. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04400084
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Jean-Marc TRELUYER, Pr
Phone 00 33 1 58 41 28 85
Email jean-marc.treluyer@parisdescartes.fr
Status Recruiting
Phase
Start date June 5, 2020
Completion date June 2030

See also
  Status Clinical Trial Phase
Completed NCT00341263 - Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies
Completed NCT01907620 - Circulating Oxidative Stress and Gestational Hypertension. Study of the Evolution of Free-radical Markers of Oxidative Stress From Before to After Childbirth in Two Groups of Women: Normal Pregnancy and Pre-eclampsia. N/A
Completed NCT03692923 - VIRTUAL COMMUNITY for PREGNANT WOMEN N/A
Recruiting NCT06133621 - Determination of Reference Values for Diluted Russell's Viper Venom Time (dRVVT) Specific to Pregnant Women (GRAPL)
Completed NCT04215484 - Placenta Accreta New Detection Procedure by Rapid Assessment of Serum BNP
Completed NCT00437996 - Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial Phase 3